APTO vs. ELEV, DYAI, IVVD, ACHL, ALVR, DTIL, ESLA, PASG, JATT, and SRZN
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Elevation Oncology (ELEV), Dyadic International (DYAI), Invivyd (IVVD), Achilles Therapeutics (ACHL), AlloVir (ALVR), Precision BioSciences (DTIL), Estrella Immunopharma (ESLA), Passage Bio (PASG), JATT Acquisition (JATT), and Surrozen (SRZN). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences vs.
Aptose Biosciences (NASDAQ:APTO) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Aptose Biosciences received 346 more outperform votes than Elevation Oncology when rated by MarketBeat users. However, 76.09% of users gave Elevation Oncology an outperform vote while only 62.77% of users gave Aptose Biosciences an outperform vote.
Elevation Oncology's return on equity of -59.73% beat Aptose Biosciences' return on equity.
Aptose Biosciences presently has a consensus price target of $4.33, suggesting a potential upside of 1,979.33%. Elevation Oncology has a consensus price target of $7.20, suggesting a potential upside of 951.09%. Given Aptose Biosciences' higher possible upside, equities research analysts plainly believe Aptose Biosciences is more favorable than Elevation Oncology.
26.6% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 1.3% of Aptose Biosciences shares are owned by company insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Aptose Biosciences and Aptose Biosciences both had 5 articles in the media. Elevation Oncology's average media sentiment score of 0.58 beat Aptose Biosciences' score of 0.12 indicating that Elevation Oncology is being referred to more favorably in the news media.
Aptose Biosciences has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.
Elevation Oncology is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Elevation Oncology beats Aptose Biosciences on 10 of the 13 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:APTO) was last updated on 1/22/2025 by MarketBeat.com Staff
